Indeed, eCBs (2-AG and anandamide) have been extensively reported to mediate short- or long-term depression, via the activation of CB1R (Kano et al., 2009; Castillo et al., 2012; Katona and Freund, 2012; Melis et al., 2014) or TRPV1 (Gibson et al., 2008; Maione et al., 2009; Chávez et al., 2010; Grueter et al., 2010; Puente et al., 2011). Here, CNR1 is linked to major depressive disorder.